IPO News | Yinuo Weimedicine's Hong Kong Stock IPO Prospectus Expires

The Zhitong Finance App learned that the Hong Kong stock prospectus submitted by Immvira Bioscience Inc. (abbreviation: Inuowei Pharmaceuticals) on June 25 expired on December 25 after 6 months. Citibank and CICC were co-sponsors when the statement was submitted.

According to the previous prospectus, Yinuo Weimedicine is a biotechnology company focusing on clinical needs. It is committed to discovering, developing, producing and commercializing novel tumoral immunotherapy and engineered exosomal therapy through bioengineering technology with independent intellectual property rights. The company designs and creates a risk-balanced product portfolio, including tumolytic immunotherapy candidates with best-in-class potential for treating solid tumors and innovative engineered exosome therapy products with clinical application prospects or direct commercialization.